OrbiMed’s AbCellera Biologics ABCL Stock Holding History

OrbiMed’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,344,568	Closed	-$11.5M	–	110
2025 Q2	$11.5M	Sell	3,344,568 -836,200	-20%	-$2.08M	0.29%	56
2025 Q1	$9.32M	Hold	4,180,768	–	–	0.22%	64
2024 Q4	$12.2M	Hold	4,180,768	–	–	0.25%	68
2024 Q3	$10.9M	Hold	4,180,768	–	–	0.2%	78
2024 Q2	$12.4M	Hold	4,180,768	–	–	0.24%	68
2024 Q1	$18.9M	Hold	4,180,768	–	–	0.35%	67
2023 Q4	$23.9M	Hold	4,180,768	–	–	0.48%	60
2023 Q3	$19.2M	Hold	4,180,768	–	–	0.41%	64
2023 Q2	$27M	Hold	4,180,768	–	–	0.49%	61
2023 Q1	$31.5M	Hold	4,180,768	–	–	0.62%	53
2022 Q4	$42.4M	Hold	4,180,768	–	–	0.81%	47
2022 Q3	$41.3M	Hold	4,180,768	–	–	0.77%	48
2022 Q2	$44.5M	Hold	4,180,768	–	–	0.81%	40
2022 Q1	$40.8M	Hold	4,180,768	–	–	0.66%	44
2021 Q4	$59.8M	Hold	4,180,768	–	–	0.77%	43
2021 Q3	$83.8M	Sell	4,180,768 -2,042,251	-33%	-$36.1M	0.92%	33
2021 Q2	$137M	Sell	6,223,019 -1,977,749	-24%	-$54.5M	1.38%	20
2021 Q1	$278M	Sell	8,200,768 -200,000	-2%	-$7.97M	2.6%	9
2020 Q4	$338M	Buy	+8,400,768	New	+$384M	2.96%	5

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

OrbiMed's ABCL Position: Q3 2025 in Review

OrbiMed sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 3,344,568 shares — an estimated $11.5M sold.

OrbiMed first reported a position in ABCL in Q4 2020 and held it in 19 quarters. The position peaked at $338M in Q4 2020. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

OrbiMed reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
OrbiMed sold 3,344,568 AbCellera Biologics shares in Q3 2025, an estimated $11.5M.
OrbiMed first reported a position in AbCellera Biologics in Q4 2020 and held it in 19 quarters.
OrbiMed's AbCellera Biologics position peaked at $338M in Q4 2020.
141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.